Key Segments:
By Therapy
-
- Targeted Therapy
- Vyndaqel/Vyndamax
- Onpattro
- Amvuttra
- Tegsedi
- Wainua
- Supportive Therapy
- Pipeline Therapy
- Targeted Therapy
By Type
-
- ATTR with Polyneuropathy (ATTR-PN)
- ATTR with Cardiomyopathy (ATTR-CM)
By Disease
-
- Hereditary Transthyretin Amyloidosis
- Polyneuropathy
- Cardiomyopathy
- Mixed Type
- Wild Type Amyloidosis
- Hereditary Transthyretin Amyloidosis
By Distribution Channel
-
- Hospital Pharmacies
- Specialty Pharmacies
- Retail Pharmacies
- Online Pharmacies
Request for Segment Customization as per your Business Requirement: https://www.snsinsider.com/enquiry/6932
Regional Coverage:
North America
- US
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Poland
- Turkey
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Australia
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Request for Country Level Research Report: https://www.snsinsider.com/enquiry/6932
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g. Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: North America dominated the Transthyretin Amyloidosis Treatment Market in 2024.
Ans: The “Targeted Therapy” segment dominated the Transthyretin Amyloidosis Treatment Market.
Ans: Increasing Incidence of ATTR propelling the Transthyretin Amyloidosis Treatment Market Trends.
Ans: The Transthyretin Amyloidosis Treatment Market was USD 7.81 billion in 2024 and is expected to reach USD 17.80 billion by 2032.
Ans: The Transthyretin Amyloidosis Treatment Market is expected to grow at a CAGR of 14.64% from 2025 to 2032.